{
  "study_id": "NCT01085136",
  "study_title": "Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial",
  "table_name": "Table 1",
  "table_title": "Patient demographics and clinical characteristics",
  "footnotes": [
    "aPaclitaxel (35.0%), docetaxel (15.0%), pemetrexed (26.7%), vinorelbine (8.3%), gemcitabine (6.7%), carboplatin (1.7%), non-protocol defined chemotherapy (6.7%).",
    "bChina, Taiwan or Korea.",
    "cDue to local regulations that did not allow the collection of such information.",
    "dDefined as CR or PR to prior EGFR TKI or â‰¥48 weeks' treatment with prior EGFR TKI."
  ],
  "groups": [
    {
      "name": "Afatinib plus paclitaxel",
      "n": 134,
      "type": "intervention"
    },
    {
      "name": "Chemotherapy",
      "n": 68,
      "type": "control"
    }
  ],
  "characteristics": [
    {
      "original_label": "Female, n (%)",
      "standardized_name": "Sex",
      "category": "Female",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 65.0,
          "percentage": 48.5,
          "raw_string": "65 (48.5)",
          "n_for_value": 134
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 34.0,
          "percentage": 50.0,
          "raw_string": "34 (50.0)",
          "n_for_value": 68
        }
      ]
    },
    {
      "original_label": "Median age (years)",
      "standardized_name": "Age",
      "unit": "years",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "numeric_median_iqr",
          "median": 60.0,
          "raw_string": "60.0"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "numeric_median_iqr",
          "median": 60.5,
          "raw_string": "60.5"
        }
      ]
    },
    {
      "original_label": "Baseline ECOG status, n (%)",
      "standardized_name": "ECOG Performance Status",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status",
      "category": "0",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Baseline ECOG status, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 47.0,
          "percentage": 35.1,
          "raw_string": "47 (35.1)",
          "n_for_value": 134
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 14.0,
          "percentage": 20.6,
          "raw_string": "14 (20.6)",
          "n_for_value": 68
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status",
      "category": "1",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Baseline ECOG status, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 77.0,
          "percentage": 57.5,
          "raw_string": "77 (57.5)",
          "n_for_value": 134
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 46.0,
          "percentage": 67.6,
          "raw_string": "46 (67.6)",
          "n_for_value": 68
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status",
      "category": "2",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Baseline ECOG status, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 7.5,
          "raw_string": "10 (7.5)",
          "n_for_value": 134
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 11.8,
          "raw_string": "8 (11.8)",
          "n_for_value": 68
        }
      ]
    },
    {
      "original_label": "Race, n (%)",
      "standardized_name": "Race",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "East Asianb",
      "standardized_name": "Race",
      "category": "East Asian",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 52.0,
          "percentage": 38.8,
          "raw_string": "52 (38.8)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 44.1,
          "raw_string": "30 (44.1)"
        }
      ]
    },
    {
      "original_label": "Caucasian",
      "standardized_name": "Race",
      "category": "Caucasian",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 53.0,
          "percentage": 39.6,
          "raw_string": "53 (39.6)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 24.0,
          "percentage": 35.3,
          "raw_string": "24 (35.3)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Race",
      "category": "Other",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.2,
          "raw_string": "3 (2.2)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 2.9,
          "raw_string": "2 (2.9)"
        }
      ]
    },
    {
      "original_label": "Unknownc",
      "standardized_name": "Race",
      "category": "Unknown",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 26.0,
          "percentage": 19.4,
          "raw_string": "26 (19.4)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 17.6,
          "raw_string": "12 (17.6)"
        }
      ]
    },
    {
      "original_label": "Smoking status, n (%)",
      "standardized_name": "Smoking Status",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Never smoked",
      "standardized_name": "Smoking Status",
      "category": "Never smoked",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 71.0,
          "percentage": 53.0,
          "raw_string": "71 (53.0)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 37.0,
          "percentage": 54.4,
          "raw_string": "37 (54.4)"
        }
      ]
    },
    {
      "original_label": "<15 pack-years, stopped >1 year before diagnosis",
      "standardized_name": "Smoking Status",
      "category": "Former smoker (<15 pack-years, stopped >1 year before diagnosis)",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 14.0,
          "percentage": 10.4,
          "raw_string": "14 (10.4)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 14.7,
          "raw_string": "10 (14.7)"
        }
      ]
    },
    {
      "original_label": "Current/other ex-smoker",
      "standardized_name": "Smoking Status",
      "category": "Current or other former smoker",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 49.0,
          "percentage": 36.6,
          "raw_string": "49 (36.6)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 30.9,
          "raw_string": "21 (30.9)"
        }
      ]
    },
    {
      "original_label": "Clinical stage at screening, n (%)",
      "standardized_name": "Clinical Stage at Screening",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "IIIb",
      "standardized_name": "Clinical Stage at Screening",
      "category": "IIIb",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Clinical stage at screening, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.7,
          "raw_string": "1 (0.7)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 4.4,
          "raw_string": "3 (4.4)"
        }
      ]
    },
    {
      "original_label": "IV",
      "standardized_name": "Clinical Stage at Screening",
      "category": "IV",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Clinical stage at screening, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 133.0,
          "percentage": 99.3,
          "raw_string": "133 (99.3)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 65.0,
          "percentage": 95.6,
          "raw_string": "65 (95.6)"
        }
      ]
    },
    {
      "original_label": "Tumor histology, n (%)",
      "standardized_name": "Tumor Histology",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Adenocarcinoma",
      "standardized_name": "Tumor Histology",
      "category": "Adenocarcinoma",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor histology, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 113.0,
          "percentage": 84.3,
          "raw_string": "113 (84.3)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 61.0,
          "percentage": 89.7,
          "raw_string": "61 (89.7)"
        }
      ]
    },
    {
      "original_label": "Squamous",
      "standardized_name": "Tumor Histology",
      "category": "Squamous",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor histology, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 8.2,
          "raw_string": "11 (8.2)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 8.8,
          "raw_string": "6 (8.8)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Tumor Histology",
      "category": "Other",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor histology, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 7.5,
          "raw_string": "10 (7.5)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.5,
          "raw_string": "1 (1.5)"
        }
      ]
    },
    {
      "original_label": "Centrally confirmed activating EGFR mutation status, n (%)",
      "standardized_name": "EGFR Mutation Status",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "EGFR Mutation Status",
      "category": "Positive",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Centrally confirmed activating EGFR mutation status, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 4.5,
          "raw_string": "6 (4.5)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 4.4,
          "raw_string": "3 (4.4)"
        }
      ]
    },
    {
      "original_label": "Negative",
      "standardized_name": "EGFR Mutation Status",
      "category": "Negative",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Centrally confirmed activating EGFR mutation status, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.5,
          "raw_string": "2 (1.5)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 4.4,
          "raw_string": "3 (4.4)"
        }
      ]
    },
    {
      "original_label": "Higher clinical enrichment criteria, n (%)d",
      "standardized_name": "Higher Clinical Enrichment Criteria",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Yes",
      "standardized_name": "Higher Clinical Enrichment Criteria",
      "category": "Yes",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Higher clinical enrichment criteria, n (%)d",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 78.0,
          "percentage": 58.2,
          "raw_string": "78 (58.2)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 42.0,
          "percentage": 61.8,
          "raw_string": "42 (61.8)"
        }
      ]
    },
    {
      "original_label": "No",
      "standardized_name": "Higher Clinical Enrichment Criteria",
      "category": "No",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Higher clinical enrichment criteria, n (%)d",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 56.0,
          "percentage": 41.8,
          "raw_string": "56 (41.8)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 26.0,
          "percentage": 38.2,
          "raw_string": "26 (38.2)"
        }
      ]
    },
    {
      "original_label": "Prior EGFR TKI therapy, n (%)",
      "standardized_name": "Prior EGFR TKI Therapy",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Erlotinib",
      "standardized_name": "Prior EGFR TKI Therapy",
      "category": "Erlotinib",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior EGFR TKI therapy, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 96.0,
          "percentage": 71.6,
          "raw_string": "96 (71.6)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 47.0,
          "percentage": 69.1,
          "raw_string": "47 (69.1)"
        }
      ]
    },
    {
      "original_label": "Gefitinib",
      "standardized_name": "Prior EGFR TKI Therapy",
      "category": "Gefitinib",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior EGFR TKI therapy, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 32.0,
          "percentage": 23.9,
          "raw_string": "32 (23.9)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 23.5,
          "raw_string": "16 (23.5)"
        }
      ]
    },
    {
      "original_label": "Both",
      "standardized_name": "Prior EGFR TKI Therapy",
      "category": "Both",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior EGFR TKI therapy, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 4.5,
          "raw_string": "6 (4.5)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 7.4,
          "raw_string": "5 (7.4)"
        }
      ]
    },
    {
      "original_label": "Lines of prior chemotherapy, n (%)",
      "standardized_name": "Lines of Prior Chemotherapy",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "Lines of Prior Chemotherapy",
      "category": "0",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Lines of prior chemotherapy, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.7,
          "raw_string": "5 (3.7)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 2.9,
          "raw_string": "2 (2.9)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "Lines of Prior Chemotherapy",
      "category": "1",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Lines of prior chemotherapy, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 41.0,
          "percentage": 30.6,
          "raw_string": "41 (30.6)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 17.6,
          "raw_string": "12 (17.6)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "Lines of Prior Chemotherapy",
      "category": "2",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Lines of prior chemotherapy, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 39.0,
          "percentage": 29.1,
          "raw_string": "39 (29.1)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 41.2,
          "raw_string": "28 (41.2)"
        }
      ]
    },
    {
      "original_label": ">2",
      "standardized_name": "Lines of Prior Chemotherapy",
      "category": ">2",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Lines of prior chemotherapy, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 49.0,
          "percentage": 36.6,
          "raw_string": "49 (36.6)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 26.0,
          "percentage": 38.2,
          "raw_string": "26 (38.2)"
        }
      ]
    },
    {
      "original_label": "Previous pemetrexed, n (%)",
      "standardized_name": "Previous Pemetrexed",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Yes",
      "standardized_name": "Previous Pemetrexed",
      "category": "Yes",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Previous pemetrexed, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 72.0,
          "percentage": 53.7,
          "raw_string": "72 (53.7)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 39.0,
          "percentage": 57.4,
          "raw_string": "39 (57.4)"
        }
      ]
    },
    {
      "original_label": "No",
      "standardized_name": "Previous Pemetrexed",
      "category": "No",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Previous pemetrexed, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 62.0,
          "percentage": 46.3,
          "raw_string": "62 (46.3)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 42.6,
          "raw_string": "29 (42.6)"
        }
      ]
    },
    {
      "original_label": "Previous taxane, n (%)",
      "standardized_name": "Previous Taxane",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Yes",
      "standardized_name": "Previous Taxane",
      "category": "Yes",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Previous taxane, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 67.0,
          "percentage": 50.0,
          "raw_string": "67 (50.0)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 38.0,
          "percentage": 55.9,
          "raw_string": "38 (55.9)"
        }
      ]
    },
    {
      "original_label": "No",
      "standardized_name": "Previous Taxane",
      "category": "No",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Previous taxane, n (%)",
      "group_data": [
        {
          "group_name": "Afatinib plus paclitaxel",
          "data_type": "categorical_count_percentage",
          "count": 67.0,
          "percentage": 50.0,
          "raw_string": "67 (50.0)"
        },
        {
          "group_name": "Chemotherapy",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 44.1,
          "raw_string": "30 (44.1)"
        }
      ]
    }
  ]
}